Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen®) or placebo

H. Weisser, B. Behnke, B. Helpap, D. Bach, M. Krieg

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: The mechanism of action of plant extracts used for the medical treatment of human benign prostatic hyperplasia (BPH) is still unknown. In this prospective, randomized, double-blind trial, we investigated the possible influence of the Sabal serrulata extract IDS 89 (Strogen®) on epithelial and stromal enzyme activities of BPH tissue. Methods: 18 patients with BPH were randomly assigned to receive 3 x 2 capsules Strogen® uno (320 mg/capsule) (n = 8) or placebo (n = 10) daily for 3 months. The activity (V(max) and K(m)) of 5α-reductase, 3α-HSOR(red), 3β-HSOR(red), and creatine kinase was determined in mechanically separated epithelium and stroma of human BPH. Results: The multivariate correlation analysis revealed a positive correlation between therapy and the following enzyme alterations: (1) In epithelium, the substrate affinity of the 5α-reductase decreased slightly (increase of K(m) value). (2) In stroma, the V(max) value of the 3α-HSOR(red) increased statistically distinctly, leading to a moderate increase of V(max)/K(m). (3) In stroma, the V(max) value of the 3β-HSOR(red) increased moderately, but not statistically significant. (4) In stroma, the V(max) value of creatine kinase increased significantly, leading to a statistically distinct increase of V(max)/K(m). Conclusion: This double-blind, placebo-controlled clinical trial with the S. serrulata extract IDS 89 revealed significant biochemical changes at the cellular level of BPH tissue. However, the alterations are merely moderate, their biochemical causes and consequences regarding the pathophysiology of BPH rather uncertain. Therefore, more studies are needed before plant extracts like IDS 89 become valid candidates likewise synthetic substances already used for medical treatment of human BPH.

Original languageEnglish
Pages (from-to)97-101
Number of pages5
JournalEuropean Urology
Volume31
Issue number1
Publication statusPublished - 1997

Fingerprint

Prostatic Hyperplasia
Placebos
Enzymes
Plant Extracts
Creatine Kinase
Therapeutics
Capsules
Oxidoreductases
Epithelium
Enzyme Therapy
Controlled Clinical Trials
IDS 89 Sabal serrulata extract
Multivariate Analysis

Keywords

  • Benign prostatic hyperplasia
  • Enzyme activity
  • Phytotherapy
  • Sabal serrulata

ASJC Scopus subject areas

  • Urology

Cite this

Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen®) or placebo. / Weisser, H.; Behnke, B.; Helpap, B.; Bach, D.; Krieg, M.

In: European Urology, Vol. 31, No. 1, 1997, p. 97-101.

Research output: Contribution to journalArticle

@article{a1a7471ca84c4e07b4430262a3f02699,
title = "Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen{\circledR}) or placebo",
abstract = "Objective: The mechanism of action of plant extracts used for the medical treatment of human benign prostatic hyperplasia (BPH) is still unknown. In this prospective, randomized, double-blind trial, we investigated the possible influence of the Sabal serrulata extract IDS 89 (Strogen{\circledR}) on epithelial and stromal enzyme activities of BPH tissue. Methods: 18 patients with BPH were randomly assigned to receive 3 x 2 capsules Strogen{\circledR} uno (320 mg/capsule) (n = 8) or placebo (n = 10) daily for 3 months. The activity (V(max) and K(m)) of 5α-reductase, 3α-HSOR(red), 3β-HSOR(red), and creatine kinase was determined in mechanically separated epithelium and stroma of human BPH. Results: The multivariate correlation analysis revealed a positive correlation between therapy and the following enzyme alterations: (1) In epithelium, the substrate affinity of the 5α-reductase decreased slightly (increase of K(m) value). (2) In stroma, the V(max) value of the 3α-HSOR(red) increased statistically distinctly, leading to a moderate increase of V(max)/K(m). (3) In stroma, the V(max) value of the 3β-HSOR(red) increased moderately, but not statistically significant. (4) In stroma, the V(max) value of creatine kinase increased significantly, leading to a statistically distinct increase of V(max)/K(m). Conclusion: This double-blind, placebo-controlled clinical trial with the S. serrulata extract IDS 89 revealed significant biochemical changes at the cellular level of BPH tissue. However, the alterations are merely moderate, their biochemical causes and consequences regarding the pathophysiology of BPH rather uncertain. Therefore, more studies are needed before plant extracts like IDS 89 become valid candidates likewise synthetic substances already used for medical treatment of human BPH.",
keywords = "Benign prostatic hyperplasia, Enzyme activity, Phytotherapy, Sabal serrulata",
author = "H. Weisser and B. Behnke and B. Helpap and D. Bach and M. Krieg",
year = "1997",
language = "English",
volume = "31",
pages = "97--101",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen®) or placebo

AU - Weisser, H.

AU - Behnke, B.

AU - Helpap, B.

AU - Bach, D.

AU - Krieg, M.

PY - 1997

Y1 - 1997

N2 - Objective: The mechanism of action of plant extracts used for the medical treatment of human benign prostatic hyperplasia (BPH) is still unknown. In this prospective, randomized, double-blind trial, we investigated the possible influence of the Sabal serrulata extract IDS 89 (Strogen®) on epithelial and stromal enzyme activities of BPH tissue. Methods: 18 patients with BPH were randomly assigned to receive 3 x 2 capsules Strogen® uno (320 mg/capsule) (n = 8) or placebo (n = 10) daily for 3 months. The activity (V(max) and K(m)) of 5α-reductase, 3α-HSOR(red), 3β-HSOR(red), and creatine kinase was determined in mechanically separated epithelium and stroma of human BPH. Results: The multivariate correlation analysis revealed a positive correlation between therapy and the following enzyme alterations: (1) In epithelium, the substrate affinity of the 5α-reductase decreased slightly (increase of K(m) value). (2) In stroma, the V(max) value of the 3α-HSOR(red) increased statistically distinctly, leading to a moderate increase of V(max)/K(m). (3) In stroma, the V(max) value of the 3β-HSOR(red) increased moderately, but not statistically significant. (4) In stroma, the V(max) value of creatine kinase increased significantly, leading to a statistically distinct increase of V(max)/K(m). Conclusion: This double-blind, placebo-controlled clinical trial with the S. serrulata extract IDS 89 revealed significant biochemical changes at the cellular level of BPH tissue. However, the alterations are merely moderate, their biochemical causes and consequences regarding the pathophysiology of BPH rather uncertain. Therefore, more studies are needed before plant extracts like IDS 89 become valid candidates likewise synthetic substances already used for medical treatment of human BPH.

AB - Objective: The mechanism of action of plant extracts used for the medical treatment of human benign prostatic hyperplasia (BPH) is still unknown. In this prospective, randomized, double-blind trial, we investigated the possible influence of the Sabal serrulata extract IDS 89 (Strogen®) on epithelial and stromal enzyme activities of BPH tissue. Methods: 18 patients with BPH were randomly assigned to receive 3 x 2 capsules Strogen® uno (320 mg/capsule) (n = 8) or placebo (n = 10) daily for 3 months. The activity (V(max) and K(m)) of 5α-reductase, 3α-HSOR(red), 3β-HSOR(red), and creatine kinase was determined in mechanically separated epithelium and stroma of human BPH. Results: The multivariate correlation analysis revealed a positive correlation between therapy and the following enzyme alterations: (1) In epithelium, the substrate affinity of the 5α-reductase decreased slightly (increase of K(m) value). (2) In stroma, the V(max) value of the 3α-HSOR(red) increased statistically distinctly, leading to a moderate increase of V(max)/K(m). (3) In stroma, the V(max) value of the 3β-HSOR(red) increased moderately, but not statistically significant. (4) In stroma, the V(max) value of creatine kinase increased significantly, leading to a statistically distinct increase of V(max)/K(m). Conclusion: This double-blind, placebo-controlled clinical trial with the S. serrulata extract IDS 89 revealed significant biochemical changes at the cellular level of BPH tissue. However, the alterations are merely moderate, their biochemical causes and consequences regarding the pathophysiology of BPH rather uncertain. Therefore, more studies are needed before plant extracts like IDS 89 become valid candidates likewise synthetic substances already used for medical treatment of human BPH.

KW - Benign prostatic hyperplasia

KW - Enzyme activity

KW - Phytotherapy

KW - Sabal serrulata

UR - http://www.scopus.com/inward/record.url?scp=0031020181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031020181&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 97

EP - 101

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 1

ER -